Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1944-1948

  Kakkar, Ajay K ^a   Levine, Mark N ^a   Kadziola, Zbigniew ^a   Lemoine, Nicholas R ^a   Low, Vanessa ^a   Patel, Heman K ^a   Rustin, Gordon ^a   Thomas, Michael ^a   Quigley, Mary ^a   Williamson, Robin C N ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; VENOUS THROMBOEMBOLISM; AGED; CANADA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; ITALY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DALTEPARIN; DOUBLE-BLIND METHOD; ENGLAND; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASMS; ONTARIO; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 3042704507     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.002     Document Type: Article

References (26)

1. Kakkar AK, Williamson RC: Antithrombotic therapy in cancer. BMJ 318:1571-1572, 1999
2. Kakkar AK, DeRuvo N, Chinswangwatanakul V, et al: Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346:1004-1005, 1995
3. Sampson MT, Kakkar AK: Coagulation proteases and human cancer. Biochem Soc Trans 30:201-207, 2002
4. Hirsh J, Levine M: Low molecular weight heparin. Blood 79:1-17, 1992
5. Rabenstein DL: Heparin and heparan sulfate: Structure and function. Nat Prod Rep 19: 312-331, 2002
6. Hirsh J, Warkentin T, Shaughnessy S, et al: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119: 64S-94S, 2001 (suppl 1)
7. Kaiser B, Hoppensteadt DA, Fareed J: Tissue factor pathway inhibitor: An update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 10:1925-1935, 2001
8. Abildgaard U: Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasia 23:103-106, 1993 (suppl 1)
9. Mismetti P, Laporte S, Darmon JY, et al: Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913-930, 2001
10. Gould MK, Dembitzer AD, Doyle RL, et al: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials. Ann Intern Med 130:800-809, 1999
11. Zacharski LR, Henderson WG, Rickles FR, et al: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final report of VA Cooperative Study #75. Cancer 53:2046-2052, 1984
12. Lebeau B, Chastang C, Brechot JM, et al: Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74:38-45, 1994
13. Green D, Hull RD, Brant R, et al: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339:1476, 1992
14. Siragusa S, Cosmi B, Piovella F, et al: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 100:269-277, 1996
15. Hettiarachchi R, Smorenburg S, Ginsberg J, et al: Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82:947-952, 1999
16. Ansell J, Hirsh J, Dalen J, et al: Managing oral anticoagulant therapy. Chest 119:22S-38S, 2001 (suppl 1)
17. Ruf W, Mueller BM: Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 3:379-384, 1996
18. Kakkar AK, Chinswangwatanakul V, Lemoine NR, et al: Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 86:890-894, 1999
19. Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of anticoagulation trial. N Engl J Med 342:1953-1958, 2000
20. Zacharski LR, Loynes JT: The heparins and cancer. Curr Opin Pulm Med 8:379-382, 2002
21. Ornstein DL, Zacharski LR: Activity of heparins in experimental models of malignancy: Possible explanations for anticancer effects in humans. Clin Hemorheol Microcirc 26:33-40, 2002
22. Cosgrove RH, Zacharski LR, Racine E, et al: Improved cancer mortality with low-molecular-weight heparin treatment: A review of the evidence. Semin Thromb Hemost 28:79-87, 2002
23. von Tempelhoff GF, Harenberg J, Niemann F, et al: Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 16:815-824, 2000
24. Borsig L, Wong R, Feramisco J, et al: Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 98:3352-3357, 2001
25. Kakkar AK, de Lorenzo F, Pineo GF, et al: Venous thromboembolism and cancer. Baillieres Clin Haematol 11:675-687, 1998
26. Levine M, Hirsh J, Gent M, et al: Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889, 1994